ONC BeiGene Ltd.
- Stocks
- Healthcare
- NASDAQ: ONC
Price (delayed)
$319
Market cap
$35.13B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$33.4B
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R)
Highlights
The company's EPS has surged by 67% YoY and by 55% QoQ
The net income has surged by 66% year-on-year and by 55% since the previous quarter
BeiGene's debt has decreased by 6% YoY but it has increased by 2.9% from the previous quarter
Key stats
What are the main financial stats of ONC
Market
Valuations
Earnings
Shares outstanding
110.14M
Market cap
$35.13B
Enterprise value
$33.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.14
Price to sales (P/S)
7.58
EV/EBIT
N/A
EV/EBITDA
337.57
EV/Sales
7.32
Revenue
$4.56B
Gross profit
$3.9B
Operating income
-$100.7M
Net income
-$177.64M
EBIT
-$91M
EBITDA
$98.95M
Free cash flow
$229.52M
Per share
Balance sheet
Liquidity
EPS
-$0.13
EPS diluted
-$0.14
Free cash flow per share
$2.12
Book value per share
$34.89
Revenue per share
$42.07
TBVPS
$57.49
Total assets
$6.3B
Total liabilities
$2.53B
Debt
$1.03B
Equity
$3.77B
Working capital
$2.1B
Debt to equity
0.27
Current ratio
1.95
Quick ratio
1.6
Net debt/EBITDA
-17.49
Margins
Efficiency
Dividend
EBITDA margin
2.2%
Gross margin
85.5%
Net margin
-3.9%
Operating margin
-2.2%
Return on assets
-3%
Return on equity
-5.1%
Return on invested capital
-4.1%
Return on capital employed
-2.2%
Return on sales
-2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ONC stock price
How has the BeiGene stock price performed over time
Intraday
3.01%
1 week
10.69%
1 month
18.28%
1 year
67.11%
YTD
72.7%
QTD
31.78%
Financial performance
How have BeiGene's revenue and profit performed over time
Revenue
$4.56B
Gross profit
$3.9B
Operating income
-$100.7M
Net income
-$177.64M
Gross margin
85.5%
Net margin
-3.9%
ONC's operating margin has surged by 92% year-on-year and by 69% since the previous quarter
BeiGene's operating income has surged by 89% YoY and by 66% QoQ
BeiGene's net margin has soared by 77% YoY and by 59% from the previous quarter
The net income has surged by 66% year-on-year and by 55% since the previous quarter
Price vs fundamentals
How does ONC's price correlate with its fundamentals
Growth
What is BeiGene's growth rate over time
Valuation
What is BeiGene stock price valuation
P/E
N/A
P/B
9.14
P/S
7.58
EV/EBIT
N/A
EV/EBITDA
337.57
EV/Sales
7.32
The company's EPS has surged by 67% YoY and by 55% QoQ
The price to book (P/B) is 53% higher than the 5-year quarterly average of 5.8 and 27% higher than the last 4 quarters average of 7.0
The equity has grown by 12% YoY and by 8% from the previous quarter
ONC's price to sales (P/S) is 66% lower than its 5-year quarterly average of 21.5 but 17% higher than its last 4 quarters average of 6.3
The revenue has grown by 47% YoY and by 9% from the previous quarter
Efficiency
How efficient is BeiGene business performance
The company's return on sales has surged by 89% YoY and by 73% QoQ
BeiGene's ROIC has soared by 86% YoY and by 71% from the previous quarter
The company's return on assets has surged by 67% YoY and by 55% QoQ
ONC's return on equity has surged by 66% year-on-year and by 56% since the previous quarter
Dividends
What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ONC.
Financial health
How did BeiGene financials performed over time
The total assets is 149% greater than the total liabilities
The total assets has increased by 10% year-on-year and by 8% since the previous quarter
ONC's total liabilities is up by 8% since the previous quarter and by 8% year-on-year
BeiGene's debt is 73% less than its equity
BeiGene's debt to equity has decreased by 16% YoY and by 3.6% QoQ
The equity has grown by 12% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.